These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A. J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666 [Abstract] [Full Text] [Related]
3. Remission of pituitary-dependent Cushing's disease after removal of nonneoplastyic pituitary gland. Taylor HC, Velasco ME, Brodkey JS. Arch Intern Med; 1980 Oct; 140(10):1366-8. PubMed ID: 6252859 [Abstract] [Full Text] [Related]
4. Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease. Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F. Acta Endocrinol (Copenh); 1983 Oct; 104(2):160-3. PubMed ID: 6314723 [Abstract] [Full Text] [Related]
5. Response to neurotransmitter modulating drugs in patients with Cushing's disease. Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F. Clin Endocrinol (Oxf); 1986 Dec; 25(6):661-7. PubMed ID: 3115630 [Abstract] [Full Text] [Related]
6. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. Lamberts SW, de Lange SA, Stefanko SZ. J Clin Endocrinol Metab; 1982 Feb; 54(2):286-91. PubMed ID: 6274899 [No Abstract] [Full Text] [Related]
7. [Unique type of Cushing's disease in clinical profile: cyclic Cushing's syndrome and Cushing's disease with favorable outcome to a high daily dose of bromocriptine]. Yasuda K, Miura K. Nihon Naibunpi Gakkai Zasshi; 1994 Jan 20; 70(1):11-6. PubMed ID: 7958078 [Abstract] [Full Text] [Related]
8. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine. Atkinson AB, Kennedy AL, Sheridan B. Postgrad Med J; 1985 Mar 20; 61(713):239-42. PubMed ID: 2984649 [Abstract] [Full Text] [Related]
9. Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease. Hayashi H, Mercado-Asis LB, Murayama M, Yamakita N, Yasuda K, Miura K. Endocrinol Jpn; 1990 Dec 20; 37(6):875-82. PubMed ID: 1966282 [Abstract] [Full Text] [Related]
10. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Whitehead HM, Beacom R, Sheridan B, Atkinson AB. Clin Endocrinol (Oxf); 1990 Feb 20; 32(2):193-201. PubMed ID: 2161298 [Abstract] [Full Text] [Related]
11. [Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine]. García Rojas JF, Mangas Rojas A, Barba Chacón A, García Osle M, Zamora Madaria E. Rev Clin Esp; 1991 Jan 20; 188(1):37-40. PubMed ID: 2063025 [Abstract] [Full Text] [Related]
12. Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine. Adachi M, Takayanagi R, Yanase T, Sakai Y, Ikuyama S, Nakagaki H, Osamura Y, Sanno N, Nawata H. Intern Med; 1996 Mar 20; 35(3):207-11. PubMed ID: 8785455 [Abstract] [Full Text] [Related]
14. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P, Stewart PM. J Clin Endocrinol Metab; 2002 Jan 20; 87(1):57-62. PubMed ID: 11788623 [Abstract] [Full Text] [Related]
15. Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? Francia G, Davì MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V. J Endocrinol Invest; 2006 Apr 20; 29(4):358-62. PubMed ID: 16699304 [Abstract] [Full Text] [Related]
16. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. Aron DC, Raff H, Findling JW. J Clin Endocrinol Metab; 1997 Jun 20; 82(6):1780-5. PubMed ID: 9177382 [Abstract] [Full Text] [Related]
17. In vivo and in vitro studies in a patient with cyclical Cushing's disease showing some responsiveness to bromocriptine. Watanobe H, Aoki R, Takebe K, Nakazono M, Kudo M. Horm Res; 1991 Jun 20; 36(5-6):227-34. PubMed ID: 1668381 [Abstract] [Full Text] [Related]
18. Use of bromocriptine for treatment of Cushing's disease caused by an adenoma originating from the intermediate lobe of the pituitary. Romer TE, Lastowiecki PM, Klimaszewski J. Endokrynol Pol; 1987 Jun 20; 38(1):97-105. PubMed ID: 3428237 [No Abstract] [Full Text] [Related]
19. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Clin Endocrinol (Oxf); 2005 Nov 20; 63(5):549-59. PubMed ID: 16268808 [Abstract] [Full Text] [Related]
20. Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease. Pieters GF, Hermus AR, Smals AG, Bartelink AK, Benraad TJ, Kloppenborg PW. J Clin Endocrinol Metab; 1983 Sep 20; 57(3):513-6. PubMed ID: 6308029 [Abstract] [Full Text] [Related] Page: [Next] [New Search]